High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma
暂无分享,去创建一个
Jia Fan | S. Qiu | Jia Fan | Jian Zhou | Meng-Xin Tian | Lei Jin | Wei-ren Liu | Yinghong Shi | Z. Dai | Zhen-Bin Ding | Lei Jin | Jian Zhou | Zhi Dai | Shuang-Jian Qiu | Zhen-Bin Ding | Liu-Xiao Yang | Ying-Hong Shi | Wei-Ren Liu | Meng-Xin Tian | Ying-Hao Shen | Yuan-Fei Peng | Liuxiao Yang | Ying-Hao Shen | Yuan-fei Peng | Yinghao Shen | Weiren Liu | Zhen–Bin Ding
[1] A. Covey,et al. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.
[2] He Huang,et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China , 2013, Proceedings of the National Academy of Sciences.
[3] W. Nelson,et al. Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma , 2012, PloS one.
[4] W. Yung,et al. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. , 2013, Neuro-oncology.
[5] M. Esteller,et al. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. , 2010, Developmental cell.
[6] Isabel B. Lokody. Metabolism: IDH2 drives cancer in vivo , 2013, Nature Reviews Cancer.
[7] A. Gambotto,et al. Expression of X‐linked inhibitor‐of‐apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence , 2008, Hepatology.
[8] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[9] Z. Wang,et al. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type , 2013, Journal of experimental & clinical cancer research : CR.
[10] Zhao-You Tang,et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Qiu,et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma , 2013, Journal of experimental & clinical cancer research : CR.
[12] J. Llovet,et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies , 2013, Oncogene.
[13] G. Schackert,et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. , 2011, Cancer research.
[14] A. Grigoriadis,et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.
[15] Yi Zhang,et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.
[16] David R. Liu,et al. Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .
[17] H. Leonhardt,et al. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA , 2010, Nucleic acids research.
[18] Jung-Il Lee,et al. Clinicopathologic and genomic features of gliosarcomas , 2012, Journal of Neuro-Oncology.
[19] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[20] Feng-Chun Yang,et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.
[21] Q. Ye,et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. , 2007, Journal of hepatology.
[22] N. Heintz,et al. The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain , 2009, Science.
[23] K. Kinzler,et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.
[24] Peter A. Jones,et al. Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.
[25] Fan Shen,et al. Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. , 2013, Clinical chemistry.
[26] M. Dawson,et al. Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.
[27] H. Aburatani,et al. Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation , 2012, Cancer science.
[28] J. Kinoshita,et al. Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer , 2011, Journal of experimental & clinical cancer research : CR.
[29] Regulation of microRNAs by epigenetics and their interplay involved in cancer , 2013, Journal of experimental & clinical cancer research : CR.
[30] Abraham J. Khorasani,et al. Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.
[31] Fang Wang,et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.
[32] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[33] M. Esteller,et al. Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.
[34] S. Qiu,et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. , 2008, Cancer research.
[35] Z. Ling,et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.